Rabinovich's 30-year research on galectins reveals how immune molecules have dual roles: helping restore immune balance or enabling tumors to evade detection. Current immunotherapy revolutionized cancer treatment but fails in many patients; galectin-based therapies offer alternative approaches for resistant cases.
El País
· May 05, 2026
· health
· 6 min de leitura
High
Apuração: Verificado
Argentine biochemist Rabinovich pursues immune system 'switches' to transform cancer treatment
Cancer patients resistant to immunotherapy lack effective treatment options; research aims to expand therapeutic alternatives for those currently told no further treatment exists.
◉
Health & Medicine
2812 artigos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% correspondência
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% correspondência
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% correspondência
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% correspondência
Weight-Loss Drugs Show Promise in Reducing Alcohol Cravings, But Clini…
infobae · 90% correspondência
Cobertura Relacionada
El Mostrador · Aug 23
Guía de alimentos a limitar para proteger la salud cardiovascular
Expertos recomiendan limitar embutidos, bebidas azucaradas y ultraprocesados para reducir riesgos cardiovasculares. La a…
OkDiario · Aug 23 La boca seca no es una molestia menor: cuándo consultar al médicoLa xerostomía o boca seca es un problema infradiagnosticado que afecta a una de cada tres personas mayores de 60 años, f…
Segre.com · Aug 23 Programa pionero de ejercicio monitorizado mejora la salud cardiopulmonar en LleidaUn programa pionero en Lleida utiliza ejercicio físico monitorizado y análisis de 30 variables metabólicas para mejorar …
El País · Aug 23 No habrá una vacuna contra el cáncer, sino una distinta para cada paciente y tumorModerna y MSD avanzan hacia la aprobación de una vacuna de ARN mensajero personalizada contra el melanoma que reduce un …
Viés e Enquadramento
⚖
El País presents a largely favorable profile of Rabinovich's scientific work with minimal critical perspective, emphasizing breakthrough discoveries while lacking independent verification or skeptical analysis.
Bias Direction
center-left
Confidence
MED
Hagiographic narrative framing: The article uses a biographical storytelling approach that celebrates Rabinovich's career trajectory, employing metaphors ('Jekyll and Hyde,' 'carambola') and emphasizing serendipity and destiny ('salvando la vida'). The framing positions scientific discovery as inevitable and transformative without questioning or nuance.
revolucionario (revolutionary)
fructífero (fruitful)
fascinada (fascinated)
dulce caso (sweet case)
salvando la vida (saving his life)
hallazgo (breakthrough discovery)
Critical scientific peer review or skepticism about galectin-1 therapeutic claims
Perspectives from competing researchers or alternative approaches to immunotherapy
Discussion of failed trials, limitations, or challenges in translating discoveries to clinical practice
Patient or clinical outcomes data (article focuses on molecular mechanisms, not real-world efficacy)
Potential conflicts of interest regarding CaixaResearch Institute affiliation
Representation of voices questioning the timeline or feasibility of proposed therapies
Impacto Geopolítico
🌎
Argentine scientist's cancer immunotherapy research relocation to Barcelona represents brain drain and potential shift in biomedical research leadership from Latin America to Europe.
Escalation Risk
low
Confidence
MED
Argentina
Spain
European Union
Latin America
Europe consolidates scientific talent and biomedical research capacity by attracting leading researchers from Latin America; Argentina loses high-value human capital in healthcare innovation; Spain/EU strengthens competitive advantage in pharmaceutical development and medical breakthroughs.
Similar to post-WWII scientific brain drain patterns where developing nations lose researchers to developed economies with superior funding and infrastructure, weakening long-term innovation capacity.
Lente Econômica
📈
Argentine biochemist's galectin research at Barcelona institute could revolutionize cancer immunotherapy and autoimmune disease treatment, potentially creating new pharmaceutical markets worth billions.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Research and development
Hospital and clinical services
Patients with immunotherapy-resistant cancers and autoimmune diseases could gain access to novel treatments, potentially reducing mortality rates and improving quality of life, though high costs may initially limit accessibility.
Governments may increase R&D funding for immunotherapy research; regulatory agencies (EMA, FDA) will need expedited approval pathways for breakthrough therapies; healthcare systems must prepare for potential high-cost drug integration and reimbursement strategies.